Short Review on the Biological Activity of Cyclodextrin-Drug Inclusion Complexes Applicable in Veterinary Therapy

Cyclodextrins (CDs) are a family of carrier molecules used to improve the pharmacokinetic parameters of therapeutic molecules. These cyclic oligosaccharides have medical and pharmaceutical applications by being able to form inclusion complexes with molecules that are poorly soluble in water. The benefits of these complexes are directed towards improving the chemical and biological properties-i.e., solubility, bioavailability, stability, non-toxicity and shelf life of drug molecules. Since the 1960s, the first inclusion complexes used in therapeutics were those with & alpha;-, & beta;- and & gamma;-CD, which proved their usefulness, but had certain degrees of particularly renal toxicity. Currently, to correct these deficiencies, & beta;-CD derivatives are most frequently used, such as sulfobutylether-& beta;-CD, hydroxypropyl-& beta;-CD, etc. Therefore, it is of interest to bring to the attention of those interested the diversity of current and potential future clinical applications of inclusion complexes in veterinary medicine and to present the contribution of these inclusion complexes in improving drug efficacy. The most important biological activities of & beta;-CD complexed molecules in the veterinary field are summarized in this short review.

Automated summary

Cyclodextrins are carrier molecules used to enhance the pharmacokinetic properties of therapeutic molecules. They form inclusion complexes with poorly soluble molecules and improve their solubility, bioavailability, stability, non-toxicity, and shelf life. β-CD derivatives, such as sulfobutylether-β-CD and hydroxypropyl-β-CD, are commonly used to overcome the toxicity issues associated with earlier inclusion complexes. This review highlights the diverse clinical applications of inclusion complexes in veterinary medicine and their contribution to improving drug efficacy, focusing on the biological activities of β-CD complexed molecules.